CTS™ KnockOut™ SR XenoFree Medium
CTS™ KnockOut™ SR XenoFree Medium
인용 및 참조 문헌 (4)
Gibco™

CTS™ KnockOut™ SR XenoFree Medium

GIBCO™ KnockOut™ SR XenoFree CTS™ enables the growth and expansion of human embryonic stem cells (hESC) and human induced pluripotent자세히 알아보기
Have Questions?
보기 방식 변경buttonViewtableView
카탈로그 번호수량
12618012100 mL
12618013500 mL
카탈로그 번호 12618012
제품 가격(KRW)
246,000
온라인 행사
Ends: 31-Dec-2025
273,000
할인액 27,000 (10%)
Each
카트에 추가하기
수량:
100 mL
제품 가격(KRW)
246,000
온라인 행사
Ends: 31-Dec-2025
273,000
할인액 27,000 (10%)
Each
카트에 추가하기
GIBCO™ KnockOut™ SR XenoFree CTS™ enables the growth and expansion of human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPSC) in a cell culture medium containing only human-derived or human recombinant proteins, to facilitate the transition of hESC and hiPSC research from the bench to the clinic.

The GIBCO™ CTS™ product line enables you to reduce your burden in qualifying reagents during your transition from research applications to clinical applications.

• Defined, xenofree medium for hESC⁄iPSC stem cell culture.
• First-to-market xenofree hESC⁄iPSC product intended for Ex Vivo tissue and cell culture processing applications.

GIBCO™ KnockOut™ SR XenoFree CTS™ does not contain bovine or other non-human, animal-derived components. Besides pluripotent stem cell culture expansion and maintenance, KnockOut™ SR XenoFree CTS™ can be used for hESC⁄hiPSC cryopreservation, derivation, and differentiation studies.

This product is not used for in vitro diagnostic purpose in some countries.
For Research Use or Manufacturing of Cell, Gene, or Tissue-Based Products. CAUTION: Not intended for direct administration into humans or animals.
사양
세포 유형Embryonic Stem Cells (ESCs), Induced Pluripotent Stem Cells (iPSCs)
용도(애플리케이션)Cell and Gene Therapy Research, Development, and Manufacturing
형식Bottle
제조 품질ISO 13485, MDSAP, FDA-registered, 21 CFR 820
제품 유형Cell Culture Supplement
수량100 mL
유통 기한12 months from date of manufacture
배송 조건Dry Ice
분류Xeno-free
형태Liquid
멸균Sterile-filtered
Unit SizeEach
구성 및 보관
Store at –5 to –20°C and protect from light.

자주 묻는 질문(FAQ)

What is CTS?

The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Do you offer a medical device–grade of CTS KnockOut SR XenoFree Medium?

Yes, we do offer a Class II medical device–labeled CTS KnockOut SR XenoFree Medium in the USA and Canada only. Please contact us at custommedia@thermofisher.com to discuss if a medical device grade is required for your application.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

How do I characterize human embryonic stem ( ES) cells?

Human ES cells are generally characterized by their typical morphology (they grow as tightly packed clusters of small cells with high ratio of nucleus to cytoplasm); surface marker expression; RT-PCR detection of stem cell-specific gene expression (such as Oct3/4, Sox2, and Nanog); alkaline phosphatase staining, and telomerase activity assay. The most commonly used ES specific surface markers include stage-specific embryonic antigens SSEA-3 and SSEA-4 for human ES cells. Other ES-specific surface antigens also include TRA-1-60 and TRA-1-81. (Science 282:1145 (1998).

How are human embryonic stem (ES) cells derived?

Human ES cells are derived from human blastocyst inner cell masses, isolated by immunosurgery with rabbit antiserum to BeWO cells (a human trophoblast cell line) (Science 282:1145 (1998)).

What are ES cells?

Embryonic stem (ES) cells are derived from the early mammalian embryo and are capable of unlimited, undifferentiated proliferation in vitro while maintaining their potential to differentiate into a wide of range of adult tissues including germ cells. The pluripotency of the ES cells is normally demonstrated in vitro by inducing ES cells to differentiate into embryoid bodies and checking lineage-specific markers for differentiated cells in three body layers (endo, meso, and ectoderm), or injecting them into immunodeficient mice and determining the cell types produced in the teratomas.

인용 및 참조 문헌 (4)

인용 및 참조 문헌
Abstract
CD133-enriched Xeno-Free human embryonic-derived neural stem cells expand rapidly in culture and do not form teratomas in immunodeficient mice.
Authors:Haus DL, Nguyen HX, Gold EM, Kamei N, Perez H, Moore HD, Anderson AJ, Cummings BJ
Journal:
PubMed ID:25082219
'Common methods for the generation of human embryonic-derived neural stem cells (hNSCs) result in cells with potentially compromised safety profiles due to maintenance of cells in conditions containing non-human proteins (e.g. in bovine serum or on mouse fibroblast feeders). Additionally, sufficient expansion of resulting hNSCs for scaling out or up ... More
An ECM-based culture system for the generation and maintenance of xeno-free human iPS cells.
Authors:Kim HT, Lee KI, Kim DW, Hwang DY
Journal:Biomaterials
PubMed ID:23153417
'Pluripotent stem cells (PSCs) including induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) have emerged as a promising source for treating incurable diseases. Problems that urgently need to be resolved before the clinical application include avoiding potential xenopathogenic transmission and immune rejection that may be caused by the ... More
Concise Review: Manufacturing of Pancreatic Endoderm Cells for Clinical Trials in Type 1 Diabetes.
Authors:Schulz TC,
Journal:
PubMed ID:26062982
'The cellular component of ViaCyte''s VC-01 combination product for type 1 diabetes, pancreatic endoderm cells (PEC-01) derived from CyT49 human embryonic stem cells, matures after transplantation and functions to regulate blood glucose in rodent models. The aims in manufacturing PEC-01 at scale are to generate a consistent and robust transplantable ... More
Generation of human-induced pluripotent stem cells by a nonintegrating RNA Sendai virus vector in feeder-free or xeno-free conditions.
Authors:Macarthur CC, Fontes A, Ravinder N, Kuninger D, Kaur J, Bailey M, Taliana A, Vemuri MC, Lieu PT,
Journal:Stem Cells Int
PubMed ID:22550511
The generation of induced pluripotent stem cells (iPSCs) from somatic cells has enabled the possibility of providing unprecedented access to patient-specific iPSC cells for drug screening, disease modeling, and cell therapy applications. However, a major obstacle to the use of iPSC for therapeutic applications is the potential of genomic modifications ... More